Invests in
Locations:
Min Investment:
$1,000,000.00Max Investment:
$30,000,000.00Target Investment:
$12,500,000.00
Skills
Education
Lists including Ryan
Investments
Work Experience
Chairman of the Board
2021
Compassionate, Comprehensive Care for Mental Health Conditions Near You. Our psychiatrists and therapists offer mental health services including clinic visits, both in-person and tele-health. We help treat patients suffering from depression, anxiety and other mental health conditions. We provide Transcranial Magnetic Stimulation (TMS) to help fight depression. We treat patients with FDA-approved esketamine, a prescription nasal spray that helps reduce depression by its clinical effectiveness.
2019
Chairman Of The Board
2019
At Gateway Learning Group, we cultivate learning, language, behavior and social skills for individuals with Autism and other special needs. Using the principles of Applied Behavior Analysis (ABA) we design and implement an individualized therapy program for each child based on his or her particular needs and interests. Our therapists are experienced in a full range of the best treatments available including Verbal Behavior, Pivotal Response Treatments, Discrete Trial Training, and the Early Start Denver Model. To provide comprehensive support for our clients and their families, we also collaborate with educators and health professionals. Most of all, we love working with each child and enjoy sharing in their sense of pride, joy and accomplishment as they succeed.
Board Member
2018
American Endovascular provides important administrative and business support services to teams of renowned medical professionals who save the limbs that others can’t. These physicians represent the “best of the best”—nationally recognized as innovators and leaders in the fields of Amputation Prevention and Endovascular & Interventional Radiology. We are committed to helping medical professionals advance minimally invasive-image guided procedures, leading the forefront of the next wave of endovascular care.
Board Member
2018
TARGET PharmaSolutions is a real world clinical data company that delivers solutions to improve clinical, medical, and commercial outcomes. The TARGET model organizes a community of stakeholders, including pharmaceutical partners, key opinion leaders, regulatory agencies, and patient advocacy groups, around a specific disease to generate real world clinical data and insights about the natural history of the disease, including treatment outcomes
2018
Chairman Of The Board
2018
Onsite Dental pioneered the concept of delivering dental care straight to the workplace in 1997. Since then, we've been providing onsite state-of-the-art care to leading employers across the nation. Onsite Dental's delivery models are customized to meet each of our client's needs, from traditional fixed-site practices, to fully self-contained "pop-ups" that require no plumbing, to sophisticated mobile practices. We offer a full range of dental services so that employees can choose Onsite Dental for the vast majority of their dental care.
General Partner
2010
Ryan brings to Norwest Venture Partners twenty-five years of healthcare experience, sixteen years as a growth equity and buyout investor. Combining deep medical knowledge and extensive strategic business experience, Ryan focuses on growth equity and buyout investments in the healthcare sector in Norwest’s Palo Alto office. Areas in which he invests include healthcare services, healthcare IT, medical devices, and pharma services. Ryan’s investments include Capsugel (sold to Lonza), Crossover Health (acquired by Gurnet Healthcare), iCardiac (acquired by ERT), Rivermend Health, Onsite Dental, Target Pharmasolutions, and Blue Cloud Pediatric Surgical Prior to joining Norwest, Ryan was a Principal with The Carlyle Group and a Venture Partner with Industry Ventures, where he focused exclusively on healthcare service, pharmaceutical, and medical device investments from large cap buyouts to growth equity to venture. At Carlyle, Ryan’s deals led to realized profitable exits of more than $2.2 billion equity value. He served as a member or observer on the Boards of Align (Nasdaq: ALGN), AqueSys, Colin Medical, ConnectiCare, MedPointe Pharma, Multiplan, NeoVista, Proteus Biomedical and Qualicaps. At Industry Ventures, Ryan executed transactions on Access Closure, Cardiofocus, Ingenuity, and Intarcia. Prior to joining Carlyle, Ryan was a consultant in the Healthcare Practice of McKinsey, where he worked with a variety of biotechnology, pharmaceutical and medical device companies on corporate, R&D and marketing strategies. Ryan has authored more than 25 peer-reviewed comparative effectiveness articles in publications such as JAMA, Lancet, Annals of Internal Medicine, and the Journal of Health Economics. Ryan holds an M.D. from the University of California, San Francisco, School of Medicine. In addition, he earned an M.S. in health research and policy, and a B.A. in psychology from Stanford University. Ryan also attended Oxford University’s Magdalen College.
2016 - 2021
Board Member
2016 - 2021
Surgery centers specializing in dentistry and oral surgery, sold to TPG Growth
2013 - 2020
Chairman of the Board
2013 - 2020
RiverMend Health is a premier provider of scientifically driven, specialty behavioral health services to those suffering from alcohol and drug dependency, dual disorders, eating disorders, obesity and chronic pain. Founded on the belief that addiction and obesity are the nation’s most pressing healthcare challenges, the company brings together the world’s preeminent experts and a nationwide network of rehabilitation facilities to conduct evidence-based treatment, research and education. - See more at: http://www.rivermendhealth.com
2014 - 2017
Board Member
2014 - 2017
iCardiac Technologies, Inc., is the world’s largest dedicated ECG core laboratory serving the pharmaceutical industry. Its team of medical and scientific experts collectively bring over 100 years of cardiology, electrophysiology, drug development, regulatory and academic experience. iCardiac team members are active contributors on several FDA working groups that are advancing the field of cardiac safety. Sold to ERT
2011 - 2017
Board Observer
2011 - 2017
Capsugel is a global leader in delivering high-quality, innovative dosage forms and solutions to its customers in the health care industry. The company’s Hard Capsule business offers customers the broadest portfolio of gelatin, vegetarian, and other specialized capsule technologies. Capsugel’s Dosage Form Solutions (DFS) business utilizes an array of proprietary technologies and specialized manufacturing capabilities to solve customers’ most pressing product development challenges, including bioavailability enhancement, modified release, abuse deterrence, biotherapeutic processing, and inhalation formulation. The company's fast-to-clinic program streamlines product development from pre-formulation through clinical and commercial supply for finished dosage forms. Headquartered in Morristown, N.J., Capsugel serves more than 4,000 customers in more than 100 countries. For additional information, visit www.capsugel.com. Sold to Lonza